. Distinct CD8(+) T cell dynamics associate with response to neoadjuvant cancer immunotherapies. Cancer Cell. 2025-04-14; doi: 10.1016/j.ccell.2025.02.026. PubMed PMID: 40086437.
. Intratumoral or Subcutaneous MK-2118, a Non-Cyclic Dinucleotide STING Agonist, With or Without Pembrolizumab for Advanced or Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2025-04-01; doi: 10.1158/1078-0432.CCR-24-2824. PubMed PMID: 39846804; PMCID: PMC11964177.
. The T cell receptor landscape of childhood brain tumors. Sci Transl Med. 2025-03-19;17(790):eadp0675. doi: 10.1126/scitranslmed.adp0675. PubMed PMID: 40106578.
. NK cells link immune-checkpoint blockade immunotherapy and response in melanoma brain metastases. J Immunother Cancer. 2025-03-18;13(3): doi: 10.1136/jitc-2025-011581. PubMed PMID: 40107674; PMCID: PMC11927483.
. Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors. J Immunother Cancer. 2025-02-20;13(2): doi: 10.1136/jitc-2024-010511. PubMed PMID: 39979069; PMCID: PMC11842995.
. Immuno-epidemiologic mapping of HLA diversity across glioma patient cohorts. Neuro Oncol. 2025-02-14; doi: 10.1093/neuonc/noaf040. PubMed PMID: 39949048.
. Advances in LAG3 cancer immunotherapeutics. Trends Cancer. 2025-01-01; doi: 10.1016/j.trecan.2024.10.009. PubMed PMID: 39603977; PMCID: PMC12047404.
. Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies. Clin Cancer Res. 2024-12-13; doi: 10.1158/1078-0432.CCR-24-0439. PubMed PMID: 39670852.
. Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors. J Immunother Cancer. 2024-11-17;12(11): doi: 10.1136/jitc-2024-009336. PubMed PMID: 39551600; PMCID: PMC11574399.
. Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomas. J Immunother Cancer. 2024-11-12;12(11): doi: 10.1136/jitc-2024-009231. PubMed PMID: 39537211; PMCID: PMC11575263.
. Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell. 2024-11-11; doi: 10.1016/j.ccell.2024.10.007. PubMed PMID: 39486411; PMCID: PMC11560503.
. A single-cell atlas deconstructs heterogeneity across multiple models in murine traumatic brain injury and identifies novel cell-specific targets. Neuron. 2024-09-25; doi: 10.1016/j.neuron.2024.06.021. PubMed PMID: 39019041; PMCID: PMC11578855.
. NETosis Impact on Tumor Biology, Radiation, and Systemic Therapy Resistance. Clin Cancer Res. 2024-09-13; doi: 10.1158/1078-0432.CCR-24-1363. PubMed PMID: 39007757; PMCID: PMC11398986.
. Jeffrey S Weber, MD, PhD (1952-2024): in memoriam to discovery, friendship and family. J Immunother Cancer. 2024-09-10;12(9): doi: 10.1136/jitc-2024-010464. PubMed PMID: 39260827.
. Assessing clonal changes in T cells over time following immunotherapy is a breeze with Cyclone. Cancer Cell. 2024-09-09;42(9):1491-1493. doi: 10.1016/j.ccell.2024.08.014. PubMed PMID: 39255774.
. Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab. J Immunother Cancer. 2024-08-13;12(8): doi: 10.1136/jitc-2024-009475. PubMed PMID: 39142718; PMCID: PMC11337706.
. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity. Cell. 2024-08-08;187(16):4373-4388.e15. doi: 10.1016/j.cell.2024.06.036. PubMed PMID: 39121849; PMCID: PMC11346583.
. LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity. Cell. 2024-08-08;187(16):4355-4372.e22. doi: 10.1016/j.cell.2024.07.016. PubMed PMID: 39121848; PMCID: PMC11323044.
. Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). J Immunother Cancer. 2024-08-03;12(8): doi: 10.1136/jitc-2024-009474. PubMed PMID: 39097413; PMCID: PMC11344531.
. Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases. J Immunother Cancer. 2024-07-22;12(7): doi: 10.1136/jitc-2024-008837. PubMed PMID: 39038918; PMCID: PMC11268044.
. Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges. Nat Rev Clin Oncol. 2024-06-01; doi: 10.1038/s41571-024-00882-2. PubMed PMID: 38509333.
. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024-06-01; doi: 10.1038/s41577-023-00973-8. PubMed PMID: 38057451; PMCID: PMC11460566.
. T Cell Exhaustion. Annu Rev Immunol. 2024-06-01; doi: 10.1146/annurev-immunol-090222-110914. PubMed PMID: 38166256.
. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024-05-10;JCO2302355. doi: 10.1200/JCO.23.02355. PubMed PMID: 38452313; PMCID: PMC11095869.
. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis. JAMA Oncol. 2024-05-01; doi: 10.1001/jamaoncol.2023.7333. PubMed PMID: 38546551; PMCID: PMC10979364.
. Unraveling the therapeutic benefit of sequenced chemo-immunotherapy. Clin Cancer Res. 2024-05-01; doi: 10.1158/1078-0432.CCR-23-3736. PubMed PMID: 38372597; PMCID: PMC11062819.
. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease. J Immunother Cancer. 2024-04-18;12(4): doi: 10.1136/jitc-2023-008378. PubMed PMID: 38641350; PMCID: PMC11029323.
. Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility. Nat Commun. 2024-04-16;15(1):2863. doi: 10.1038/s41467-024-46906-4. PubMed PMID: 38627362; PMCID: PMC11021475.
. An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma. Cell Rep. 2024-01-23;43(1):113557. doi: 10.1016/j.celrep.2023.113557. PubMed PMID: 38113141.
. Tumor-Associated Macrophages in Merkel Cell Carcinoma: Old Balances, New Checks. Clin Cancer Res. 2024-01-17;OF1-OF3. doi: 10.1158/1078-0432.CCR-23-3320. PubMed PMID: 38230965.
. Uncovering the potential of CD40 agonism to enhance immune-checkpoint blockade. Clin Cancer Res. 2024-01-05; doi: 10.1158/1078-0432.CCR-23-2437. PubMed PMID: 37870487; PMCID: PMC10842335.
. Tumor-associated Macrophages in Merkel Cell Carcinoma: Old Balances, New Checks. Clin Cancer Res. 2024-01-03; doi: 10.1158/1078-0432.CCR-23-3320. PubMed PMID: 38170200.
. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023-11-01; doi: 10.1038/s41591-023-02583-2. PubMed PMID: 37845511; PMCID: PMC10667090.
. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023-11-01; doi: 10.1038/s41591-023-02593-0. PubMed PMID: 37857711; PMCID: PMC10667103.
. CD4+ TIL to the rescue of anti-PD-1 failure by targeting MHC-II. Clin Cancer Res. 2023-10-02; doi: 10.1158/1078-0432.CCR-23-1333. PubMed PMID: 37534980; PMCID: PMC10592266.
. Integrated BATF transcriptional network regulates suppressive intratumoral regulatory T cells. Sci Immunol. 2023-09-15;8(87):eadf6717. doi: 10.1126/sciimmunol.adf6717. PubMed PMID: 37713508; PMCID: PMC11045170.
. Debating Sentinel Lymph Node Biopsy for Melanoma in the Modern Adjuvant Era. J Clin Oncol. 2023-09-10;JCO2300255. doi: 10.1200/JCO.23.00255. PubMed PMID: 37410978; PMCID: PMC10852382.
. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023-09-01;24(9):1415-1422. doi: 10.1038/s41590-023-01569-z. PubMed PMID: 37488429; PMCID: PMC11144386.
. PD-1 Monotherapy Reigns Supreme in Adjuvant Melanoma…But for How Long? Clin Cancer Res. 2023-09-01;29(17):3253-3255. doi: 10.1158/1078-0432.CCR-23-1194. PubMed PMID: 37378689; PMCID: PMC10527539.
. CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade. Clin Cancer Res. 2023-07-05;29(13):2345-2347. doi: 10.1158/1078-0432.CCR-23-0490. PubMed PMID: 37097465; PMCID: PMC10330271.
. Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clin Cancer Res. 2023-07-05;29(13):2435-2444. doi: 10.1158/1078-0432.CCR-23-0118. PubMed PMID: 37227176; PMCID: PMC11225568.
. Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial. Lancet Digit Health. 2023-06-01;5(6):e360-e369. doi: 10.1016/S2589-7500(23)00046-8. PubMed PMID: 37087370; PMCID: PMC10245380.
. Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023-05-15;133(10): doi: 10.1172/JCI162260. PubMed PMID: 37183819; PMCID: PMC10178837.
. Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies. Clin Cancer Res. 2023-05-09; doi: 10.1158/1078-0432.CCR-23-0118. PubMed PMID: 37159185.
. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. JAMA Dermatol. 2023-05-01;159(5):545-553. doi: 10.1001/jamadermatol.2023.0127. PubMed PMID: 36920356; PMCID: PMC11225588.
. IFNγ-induction of T(H)1-like regulatory T cells controls antiviral responses. Nat Immunol. 2023-05-01;24(5):841-854. doi: 10.1038/s41590-023-01453-w. PubMed PMID: 36928412; PMCID: PMC10224582.
. Myeloid Maturity: ATRA to Enhance Anti-PD-1? Clin Cancer Res. 2023-04-03;29(7):1167-1169. doi: 10.1158/1078-0432.CCR-22-3652. PubMed PMID: 36656164; PMCID: PMC10073251.
. Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment. Nat Cancer. 2023-04-01;4(4):516-534. doi: 10.1038/s43018-023-00527-w. PubMed PMID: 36927792; PMCID: PMC11194444.
. Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy. Clin Cancer Res. 2023-03-01;29(5):835-837. doi: 10.1158/1078-0432.CCR-22-3312. PubMed PMID: 36534010; PMCID: PMC9992241.
. Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells. Immunity. 2023-02-14;56(2):369-385.e6. doi: 10.1016/j.immuni.2023.01.003. PubMed PMID: 36720219; PMCID: PMC10182785.
. Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor Subclones. Clin Cancer Res. 2023-02-01;29(3):505-507. doi: 10.1158/1078-0432.CCR-22-3022. PubMed PMID: 36383142; PMCID: PMC9898080.
. Targeting Cbl-b in cancer immunotherapy. J Immunother Cancer. 2023-02-01;11(2): doi: 10.1136/jitc-2022-006007. PubMed PMID: 36750253; PMCID: PMC9906388.
. In memoriam: Soldano Ferrone, MD, PhD (1940-2023). J Immunother Cancer. 2023-01-30;11(1): doi: 10.1136/jitc-2023-006761. PubMed PMID: 36717185; PMCID: PMC9887713.
. Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma. J Clin Oncol. 2023-01-20;41(3):443-446. doi: 10.1200/JCO.22.01770. PubMed PMID: 36162010; PMCID: PMC9870232.
. Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 2023-01-20;41(3):425-435. doi: 10.1200/JCO.22.02264. PubMed PMID: 36649675.
. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023-01-10;41(2):186-197. doi: 10.1200/JCO.22.01763. PubMed PMID: 36166727; PMCID: PMC9839305.
. Microbiome-derived metabolites counteract tumor-induced immunosuppression and boost immune checkpoint blockade. Cell Metab. 2022-12-06;34(12):1903-1905. doi: 10.1016/j.cmet.2022.11.010. PubMed PMID: 36476933.
. Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy. Clin Cancer Res. 2022-12-01;28(23):5030-5039. doi: 10.1158/1078-0432.CCR-21-2390. PubMed PMID: 35579997; PMCID: PMC9669281.
. Quantitative Spatial Profiling of TILs as the Next Step beyond PD-L1 Testing for Immune Checkpoint Blockade. Clin Cancer Res. 2022-11-14;28(22):4835-4837. doi: 10.1158/1078-0432.CCR-22-2277. PubMed PMID: 36103258; PMCID: PMC9669208.
. Hereditary Cancer Syndromes-A Broader Clinical Spectrum Than Previously Understood? JAMA Oncol. 2022-11-01;8(11):1698-1699. doi: 10.1001/jamaoncol.2022.3776. PubMed PMID: 36048458.
. Therapeutic targeting of regulatory T cells in cancer. Trends Cancer. 2022-11-01;8(11):944-961. doi: 10.1016/j.trecan.2022.06.008. PubMed PMID: 35853825; PMCID: PMC9588644.
. Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy. Clin Cancer Res. 2022-10-14;28(20):4370-4384. doi: 10.1158/1078-0432.CCR-21-1129. PubMed PMID: 35748749; PMCID: PMC9561605.
. A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma. J Am Acad Dermatol. 2022-10-01;87(4):906-908. doi: 10.1016/j.jaad.2022.05.008. PubMed PMID: 35551967; PMCID: PMC9085439.
. Autoantibodies as Predictors for Clinical Outcome and Toxicity for Immunotherapy. Clin Cancer Res. 2022-09-15;28(18):3914-3916. doi: 10.1158/1078-0432.CCR-22-1664. PubMed PMID: 36106401; PMCID: PMC9494631.
. Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022-09-15;28(18):3990-4002. doi: 10.1158/1078-0432.CCR-22-0339. PubMed PMID: 35499569; PMCID: PMC9475244.
. Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed? - Authors' reply. Lancet. 2022-08-20;400(10352):559-560. doi: 10.1016/S0140-6736(22)01350-2. PubMed PMID: 35988561.
. Neoadjuvant immunotherapy of locoregionally advanced solid tumors. J Immunother Cancer. 2022-08-01;10(8): doi: 10.1136/jitc-2022-005036. PubMed PMID: 35973745; PMCID: PMC9386211.
. Optimal systemic therapy for high-risk resectable melanoma. Nat Rev Clin Oncol. 2022-07-01;19(7):431-439. doi: 10.1038/s41571-022-00630-4. PubMed PMID: 35468949; PMCID: PMC11075933.
. Autoreactive CD8(+) T cells are restrained by an exhaustion-like program that is maintained by LAG3. Nat Immunol. 2022-06-01;23(6):868-877. doi: 10.1038/s41590-022-01210-5. PubMed PMID: 35618829; PMCID: PMC9179227.
. Tim-3 mediates T cell trogocytosis to limit antitumor immunity. J Clin Invest. 2022-05-02;132(9): doi: 10.1172/JCI152864. PubMed PMID: 35316223; PMCID: PMC9057587.
. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation. Nat Immunol. 2022-05-01;23(5):757-767. doi: 10.1038/s41590-022-01176-4. PubMed PMID: 35437325; PMCID: PMC9106921.
. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022-04-30;399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. PubMed PMID: 35367007.
. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. J Clin Oncol. 2022-04-10;40(11):1174-1185. doi: 10.1200/JCO.21.01755. PubMed PMID: 35007144; PMCID: PMC8987226.
. Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2022-04-01;28(7):1335-1344. doi: 10.1158/1078-0432.CCR-21-0426. PubMed PMID: 35091445; PMCID: PMC9164766.
. Reply to A.S. Garden. J Clin Oncol. 2022-04-01;40(10):1133-1134. doi: 10.1200/JCO.22.00063. PubMed PMID: 35171688.
. Catch and release: freeing up PD-L1 ameliorates autoimmunity. Nat Immunol. 2022-03-01;23(3):344-346. doi: 10.1038/s41590-022-01140-2. PubMed PMID: 35190718; PMCID: PMC9809504.
. Interferon-γ: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022-03-01;22(3):158-172. doi: 10.1038/s41577-021-00566-3. PubMed PMID: 34155388; PMCID: PMC8688586.
. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2022-02-15;28(4):677-688. doi: 10.1158/1078-0432.CCR-21-1963. PubMed PMID: 34716197.
. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. J Immunother Cancer. 2022-02-01;10(2): doi: 10.1136/jitc-2021-004089. PubMed PMID: 35135866; PMCID: PMC8830302.
. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol. 2022-01-10;40(2):138-149. doi: 10.1200/JCO.21.01752. PubMed PMID: 34699271; PMCID: PMC8718241.
. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. J Immunother Cancer. 2022-01-01;10(1): doi: 10.1136/jitc-2021-004310. PubMed PMID: 35074904; PMCID: PMC8788316.
. The current landscape of immunotherapy for pediatric brain tumors. Nat Cancer. 2022-01-01;3(1):11-24. doi: 10.1038/s43018-021-00319-0. PubMed PMID: 35121998.
. People critically ill with COVID-19 exhibit peripheral immune profiles predictive of mortality and reflective of SARS-CoV-2 lung viral burden. Cell Rep Med. 2021-12-21;2(12):100476. doi: 10.1016/j.xcrm.2021.100476. PubMed PMID: 34873589; PMCID: PMC8636386.
. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021-12-17;12(1):7338. doi: 10.1038/s41467-021-27619-4. PubMed PMID: 34921143; PMCID: PMC8683505.
. Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. Sci Transl Med. 2021-12-08;13(623):eabf8495. doi: 10.1126/scitranslmed.abf8495. PubMed PMID: 34878821; PMCID: PMC9022491.
. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. J Natl Cancer Inst. 2021-11-29;113(12):1733-1743. doi: 10.1093/jnci/djab108. PubMed PMID: 34097070; PMCID: PMC8634452.
. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer. 2021-11-01;9(11): doi: 10.1136/jitc-2021-003675. PubMed PMID: 34782430; PMCID: PMC8593702.
. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021-10-15;27(20):5510-5518. doi: 10.1158/1078-0432.CCR-21-0810. PubMed PMID: 34168049.
. A Cre-driven allele-conditioning line to interrogate CD4(+) conventional T cells. Immunity. 2021-10-12;54(10):2209-2217.e6. doi: 10.1016/j.immuni.2021.08.029. PubMed PMID: 34551314.
. Ipilimumab Combination Dosing: Less is More. Clin Cancer Res. 2021-10-01;27(19):5153-5155. doi: 10.1158/1078-0432.CCR-21-2406. PubMed PMID: 34341015; PMCID: PMC8807780.
. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. Ann Intern Med. 2021-09-01;174(9):1345. doi: 10.7326/L21-0441. PubMed PMID: 34543597.
. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021-08-20;39(24):2647-2655. doi: 10.1200/JCO.21.00079. PubMed PMID: 33945288; PMCID: PMC8376314.
. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J Natl Cancer Inst. 2021-08-02;113(8):1005-1016. doi: 10.1093/jnci/djab004. PubMed PMID: 33523233; PMCID: PMC8328980.
. Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma. Clin Cancer Res. 2021-08-01;27(15):4195-4204. doi: 10.1158/1078-0432.CCR-20-4301. PubMed PMID: 33753453; PMCID: PMC8338751.
. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021-08-01;9(8): doi: 10.1136/jitc-2021-002597. PubMed PMID: 34389617; PMCID: PMC8365813.
. Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver? J Immunother Cancer. 2021-07-01;9(7): doi: 10.1136/jitc-2021-002820. PubMed PMID: 34312244; PMCID: PMC8314703.
. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J Immunother Cancer. 2021-06-01;9(6): doi: 10.1136/jitc-2021-002568. PubMed PMID: 34083421; PMCID: PMC8183204.
. Reply to N. Hirshoren et al and D. Chakrabarti et al. J Clin Oncol. 2021-05-10;39(14):1600-1601. doi: 10.1200/JCO.21.00027. PubMed PMID: 33705206.
. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021-05-01;9(5): doi: 10.1136/jitc-2021-002535. PubMed PMID: 33963015; PMCID: PMC8108687.
. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck. J Immunother Cancer. 2021-05-01;9(5): doi: 10.1136/jitc-2020-002088. PubMed PMID: 33986123; PMCID: PMC8126285.
. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021-02-05;371(6529):595-602. doi: 10.1126/science.abf3363. PubMed PMID: 33542131; PMCID: PMC8097968.
. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021-02-01;9(2): doi: 10.1136/jitc-2020-002015. PubMed PMID: 33608377; PMCID: PMC7898862.
. Understanding adverse events of immunotherapy: A mechanistic perspective. J Exp Med. 2021-01-04;218(1): doi: 10.1084/jem.20192179. PubMed PMID: 33601411; PMCID: PMC7754677.
. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020-12-15;26(24):6437-6444. doi: 10.1158/1078-0432.CCR-20-1790. PubMed PMID: 33028595; PMCID: PMC8561652.
. Cancer vaccine induces potent T cell responses - but is it enough? Nat Rev Clin Oncol. 2020-12-01;17(12):721-722. doi: 10.1038/s41571-020-00437-1. PubMed PMID: 32978607.
. Evolving Evidence in Support of Sentinel Lymph Node Biopsy for Early-Stage Oral Cavity Cancer. J Clin Oncol. 2020-12-01;38(34):3983-3986. doi: 10.1200/JCO.20.02716. PubMed PMID: 33052758.
. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. Genome Med. 2020-10-27;12(1):90. doi: 10.1186/s13073-020-00787-6. PubMed PMID: 33106165; PMCID: PMC7590690.
. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clin Cancer Res. 2020-10-15;26(20):5520-5533. doi: 10.1158/1078-0432.CCR-20-0575. PubMed PMID: 32591463; PMCID: PMC8045409.
. Advances in skin science enable the development of a COVID-19 vaccine. J Am Acad Dermatol. 2020-10-01;83(4):1226-1227. doi: 10.1016/j.jaad.2020.05.126. PubMed PMID: 32485211; PMCID: PMC7260504.
. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020-10-01;21(10):1283-1295. doi: 10.1016/S1470-2045(20)30465-4. PubMed PMID: 33002436.
. Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020-09-01;6(9):797-810. doi: 10.1016/j.trecan.2020.05.009. PubMed PMID: 32540454.
. Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity. Nat Immunol. 2020-09-01;21(9):1010-1021. doi: 10.1038/s41590-020-0733-2. PubMed PMID: 32661362; PMCID: PMC7442600.
. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020-09-01;8(2): doi: 10.1136/jitc-2020-000957. PubMed PMID: 32900861; PMCID: PMC7477968.
. T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect. Nat Commun. 2020-08-24;11(1):4227. doi: 10.1038/s41467-020-17991-y. PubMed PMID: 32839441; PMCID: PMC7445289.
. PD-1 Blockade in Chinese versus Western Patients with Melanoma. Clin Cancer Res. 2020-08-15;26(16):4171-4173. doi: 10.1158/1078-0432.CCR-20-1558. PubMed PMID: 32487680; PMCID: PMC7442612.
. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response. Clin Cancer Res. 2020-08-01;26(15):3901-3907. doi: 10.1158/1078-0432.CCR-19-1321. PubMed PMID: 32332013; PMCID: PMC7607412.
. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Sci Immunol. 2020-07-17;5(49): doi: 10.1126/sciimmunol.abc2728. PubMed PMID: 32680952; PMCID: PMC7901539.
. ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19. J Immunother Cancer. 2020-07-01;8(2): doi: 10.1136/jitc-2020-001020. PubMed PMID: 32675312; PMCID: PMC7372174.
. Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. J Immunother Cancer. 2020-07-01;8(2): doi: 10.1136/jitc-2020-000967. PubMed PMID: 32675311; PMCID: PMC7368550.
. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020-06-01;8(1): doi: 10.1136/jitc-2019-000331. PubMed PMID: 32581057; PMCID: PMC7319717.
. Biology confirmed but biomarkers elusive in melanoma immunotherapy. Nat Rev Clin Oncol. 2020-04-01;17(4):198-199. doi: 10.1038/s41571-020-0328-8. PubMed PMID: 31974501.
. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2020-02-20;38(6):567-575. doi: 10.1200/JCO.19.01381. PubMed PMID: 31880964; PMCID: PMC7030886.
. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clin Cancer Res. 2020-02-15;26(4):804-811. doi: 10.1158/1078-0432.CCR-19-1223. PubMed PMID: 31558480; PMCID: PMC7055933.
. Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. Immunity. 2020-01-14;52(1):183-199.e9. doi: 10.1016/j.immuni.2019.11.014. PubMed PMID: 31924475; PMCID: PMC7201194.
. Dissolving undercut microneedle arrays for multicomponent cutaneous vaccination. J Control Release. 2020-01-10;317336-346. doi: 10.1016/j.jconrel.2019.11.023. PubMed PMID: 31756393; PMCID: PMC8237702.
. PD-1 immunotherapy for recurrent or metastatic HNSCC. Lancet. 2019-11-23;394(10212):1882-1884. doi: 10.1016/S0140-6736(19)32539-5. PubMed PMID: 31679948.
. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019-11-01;20(11):1425-1434. doi: 10.1038/s41590-019-0512-0. PubMed PMID: 31611702.
. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019-11-01;16(11):669-683. doi: 10.1038/s41571-019-0227-z. PubMed PMID: 31189965.
. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. J Immunother Cancer. 2019-10-23;7(1):274. doi: 10.1186/s40425-019-0740-8. PubMed PMID: 31647026; PMCID: PMC6813065.
. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019-09-01;25(17):5221-5230. doi: 10.1158/1078-0432.CCR-18-3944. PubMed PMID: 31239321; PMCID: PMC7721346.
. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8(+) T Cell-Derived Interferon-γ. Immunity. 2019-08-20;51(2):381-397.e6. doi: 10.1016/j.immuni.2019.06.017. PubMed PMID: 31350177; PMCID: PMC6703933.
. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019-07-15;7(1):184. doi: 10.1186/s40425-019-0662-5. PubMed PMID: 31307547; PMCID: PMC6632213.
. Positron Emission Tomography/Computed Tomography in Evaluation of the Clinically N0 Neck in Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2019-07-10;37(20):1683-1685. doi: 10.1200/JCO.19.00544. PubMed PMID: 31150317; PMCID: PMC6638595.
. PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: Understanding the Upside of the Downside of Checkpoint Blockade. JAMA Oncol. 2019-07-01;5(7):942-943. doi: 10.1001/jamaoncol.2019.0413. PubMed PMID: 31021377.
. Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 2019-06-01;20(6):724-735. doi: 10.1038/s41590-019-0346-9. PubMed PMID: 30936494; PMCID: PMC6531353.
. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma. J Immunother Cancer. 2019-04-24;7(1):113. doi: 10.1186/s40425-019-0552-x. PubMed PMID: 31014399; PMCID: PMC6480917.
. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply. N Engl J Med. 2019-03-07;380(10):987-988. doi: 10.1056/NEJMc1900150. PubMed PMID: 30855757.
. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma. Clin Cancer Res. 2019-01-15;25(2):524-532. doi: 10.1158/1078-0432.CCR-18-2258. PubMed PMID: 30420448; PMCID: PMC6335150.
. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019-01-01;5(1):74-82. doi: 10.1001/jamaoncol.2018.4224. PubMed PMID: 30242306; PMCID: PMC6439773.
. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. JAMA Oncol. 2018-11-01;4(11):1583-1588. doi: 10.1001/jamaoncol.2018.1888. PubMed PMID: 29931076; PMCID: PMC6248084.
. Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol. 2018-10-25;36(35):JCO1800632. doi: 10.1200/JCO.18.00632. PubMed PMID: 30359157; PMCID: PMC6286160.
. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer. 2018-10-23;6(1):112. doi: 10.1186/s40425-018-0428-5. PubMed PMID: 30352626; PMCID: PMC6199801.
. Novel Effector Phenotype of Tim-3(+) Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clin Cancer Res. 2018-09-15;24(18):4529-4538. doi: 10.1158/1078-0432.CCR-17-1350. PubMed PMID: 29712685; PMCID: PMC6139056.
. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer. 2018-08-31;6(1):83. doi: 10.1186/s40425-018-0393-z. PubMed PMID: 30170622; PMCID: PMC6117978.
. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018-07-01;19(7):916-929. doi: 10.1016/S1470-2045(18)30254-7. PubMed PMID: 29908991.
. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018-06-18;6(1):57. doi: 10.1186/s40425-018-0360-8. PubMed PMID: 29914571; PMCID: PMC6006764.
. Adjuvant Therapy in Resected Melanoma. N Engl J Med. 2018-02-15;378(7):679-680. doi: 10.1056/NEJMc1716071. PubMed PMID: 29443674.
. Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res. 2018-02-01;24(3):511-520. doi: 10.1158/1078-0432.CCR-16-3001. PubMed PMID: 28801472; PMCID: PMC5796849.
. Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res. 2018-01-01;24(1):62-72. doi: 10.1158/1078-0432.CCR-17-0357. PubMed PMID: 29061643; PMCID: PMC5754237.
. PD-1 Status in CD8(+) T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. Cancer Res. 2017-11-15;77(22):6353-6364. doi: 10.1158/0008-5472.CAN-16-3167. PubMed PMID: 28904066; PMCID: PMC5690836.
. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res. 2017-11-15;23(22):6888-6892. doi: 10.1158/1078-0432.CCR-17-1317. PubMed PMID: 28790109; PMCID: PMC5690823.
. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017-11-09;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. PubMed PMID: 28891408.
. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer. 2017-09-19;5(1):74. doi: 10.1186/s40425-017-0279-5. PubMed PMID: 28923120; PMCID: PMC5604296.
. A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes. JAMA Oncol. 2017-08-01;3(8):1112-1115. doi: 10.1001/jamaoncol.2016.6779. PubMed PMID: 28241191; PMCID: PMC5552417.
. Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity. J Clin Invest. 2017-06-30;127(7):2765-2776. doi: 10.1172/JCI85736. PubMed PMID: 28604385; PMCID: PMC5490746.
. Interferon-γ Drives T(reg) Fragility to Promote Anti-tumor Immunity. Cell. 2017-06-01;169(6):1130-1141.e11. doi: 10.1016/j.cell.2017.05.005. PubMed PMID: 28552348; PMCID: PMC5509332.
. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α. Clin Cancer Res. 2017-05-01;23(9):2346-2355. doi: 10.1158/1078-0432.CCR-15-1823. PubMed PMID: 27799249; PMCID: PMC5411325.
. LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes. Sci Immunol. 2017-03-31;2(9): doi: 10.1126/sciimmunol.aah4569. PubMed PMID: 28783703; PMCID: PMC5609824.
. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol. 2017-03-10;35(8):885-892. doi: 10.1200/JCO.2016.70.2951. PubMed PMID: 28135150; PMCID: PMC5455684.
. Nivolumab for Squamous-Cell Cancer of Head and Neck. N Engl J Med. 2017-02-09;376(6):596. doi: 10.1056/NEJMc1615565. PubMed PMID: 28177863.
. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. Clin Cancer Res. 2017-02-01;23(3):707-716. doi: 10.1158/1078-0432.CCR-16-0879. PubMed PMID: 27496866; PMCID: PMC5290200.
. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016-11-10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. PubMed PMID: 27718784; PMCID: PMC5564292.
. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. Clin Cancer Res. 2016-11-01;22(21):5229-5237. doi: 10.1158/1078-0432.CCR-15-2971. PubMed PMID: 27217441; PMCID: PMC5093040.
. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. Neuro Oncol. 2016-10-01;18(10):1442-50. doi: 10.1093/neuonc/now038. PubMed PMID: 27006176; PMCID: PMC5035517.
. It's TIME for a biomarker-driven approach to cancer immunotherapy. J Immunother Cancer. 2016-08-16;443. doi: 10.1186/s40425-016-0147-8. PubMed PMID: 27532018; PMCID: PMC4986195.
. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro Oncol. 2016-08-01;18(8):1157-68. doi: 10.1093/neuonc/now026. PubMed PMID: 26984745; PMCID: PMC4933485.
. Cancer immunotherapy trials: leading a paradigm shift in drug development. J Immunother Cancer. 2016-07-19;442. doi: 10.1186/s40425-016-0146-9. PubMed PMID: 27437105; PMCID: PMC4949883.
. Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. Immunity. 2016-05-17;44(5):1034-51. doi: 10.1016/j.immuni.2016.04.017. PubMed PMID: 27192568; PMCID: PMC4873959.
. Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res. 2016-04-15;22(8):1856-64. doi: 10.1158/1078-0432.CCR-15-1849. PubMed PMID: 27084739; PMCID: PMC4872712.
. Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res. 2016-03-01;76(5):1031-43. doi: 10.1158/0008-5472.CAN-15-2001. PubMed PMID: 26676749; PMCID: PMC4775348.
. Interleukin-35 Limits Anti-Tumor Immunity. Immunity. 2016-02-16;44(2):316-29. doi: 10.1016/j.immuni.2016.01.013. PubMed PMID: 26872697; PMCID: PMC4758699.
. CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux. Clin Cancer Res. 2015-12-15;21(24):5412-4. doi: 10.1158/1078-0432.CCR-14-3132. PubMed PMID: 26672083; PMCID: PMC4683414.
. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Compl J Clin Oncol. 2015-12-01;33(34):4066-76. doi: 10.1200/JCO.2015.62.0500. PubMed PMID: 26351350; PMCID: PMC4669592.
. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. J Immunother Cancer. 2015-11-17;354. doi: 10.1186/s40425-015-0097-6. PubMed PMID: 26579227; PMCID: PMC4647471.
. Chemotherapy--A Viable Partner for Cancer Immunotherapy? JAMA Oncol. 2015-11-01;1(8):1095-7. doi: 10.1001/jamaoncol.2015.2733. PubMed PMID: 26291503.
. Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer. J Immunother Cancer. 2015-10-20;349. doi: 10.1186/s40425-015-0092-y. PubMed PMID: 26500777; PMCID: PMC4617860.
. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol. 2015-10-10;33(29):3293-304. doi: 10.1200/JCO.2015.61.1509. PubMed PMID: 26351330; PMCID: PMC4586169.
. Transoral Endoscopic Head and Neck Surgery and Its Role Within the Multidisciplinary Treatment Paradigm of Oropharynx Cancer: Robotics, Lasers, and Clinical Trials. J Clin Oncol. 2015-10-10;33(29):3285-92. doi: 10.1200/JCO.2015.62.3157. PubMed PMID: 26351337; PMCID: PMC4586168.
. Persistent Salivary Human Papillomavirus DNA as a Surveillance Biomarker: Not Just Spitting in the Wind. JAMA Oncol. 2015-10-01;1(7):915-7. doi: 10.1001/jamaoncol.2015.2606. PubMed PMID: 26226055.
. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015-09-15;339. doi: 10.1186/s40425-015-0081-1. PubMed PMID: 26380086; PMCID: PMC4570556.
. Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study. J Clin Oncol. 2015-08-01;33(22):2464-71. doi: 10.1200/JCO.2014.59.5132. PubMed PMID: 26101244; PMCID: PMC4507465.
. CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Res. 2015-06-01;75(11):2200-10. doi: 10.1158/0008-5472.CAN-14-2788. PubMed PMID: 25832655; PMCID: PMC4452385.
. IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. Cancer Res. 2015-04-15;75(8):1635-44. doi: 10.1158/0008-5472.CAN-14-3016. PubMed PMID: 25720800; PMCID: PMC4401638.
. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 2015-02-01;75(3):508-518. doi: 10.1158/0008-5472.CAN-14-1215. PubMed PMID: 25480946; PMCID: PMC4315704.
. "Toll"-erance in the skin. Immunity. 2014-11-20;41(5):677-9. doi: 10.1016/j.immuni.2014.11.003. PubMed PMID: 25517608.
. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and n J Clin Oncol. 2014-07-01;32(19):2050-8. doi: 10.1200/JCO.2013.54.0526. PubMed PMID: 24888813; PMCID: PMC4067943.
. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol. 2009-12-10;27(35):5911-8. doi: 10.1200/JCO.2009.23.3494. PubMed PMID: 19805669; PMCID: PMC2793039.
. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res. 2007-07-01;13(13):3951-9. doi: 10.1158/1078-0432.CCR-07-0374. PubMed PMID: 17606729.
. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res. 2005-12-01;65(23):11146-55. doi: 10.1158/0008-5472.CAN-05-0772. PubMed PMID: 16322265.
